You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-Study appears in online edition- NORTHBROOK, Ill. and SAN FRANCISCO, Jan. 13, 2016 /PRNewswire/ -- Astellas US LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation,...
NORTHBROOK, Ill., Dec. 17, 2015 /PRNewswire/ -- Astellas Pharma today announced that the company's President and CEO Yoshihiko Hatanaka will present at the 34th Annual J.P. Morgan Healthcare...
Read more about Astellas to Present at J.P. Morgan Healthcare Conference
NORTHBROOK, Ill., Dec. 9, 2015 /PRNewswire/ -- Astellas today announced that results from the pivotal Phase 3 SECURE trial evaluating CRESEMBA® (isavuconazonium sulfate) in adult patients with...
-- Updated results evaluating safety, tolerability and antileukemic activity of gilteritinib in AML, a rare, aggressive blood cancer, presented at American Society of Hematology annual meeting --...
Moburg to lead stakeholder engagement initiatives in the U.S. and in support of the Americas NORTHBROOK, IL, Dec. 3, 2015 — Astellas Pharma recently announced that Christeen Moburg has been...
Read more about Christeen Moburg joins Astellas Pharma Corporate Affairs Team
Follow U.S. news
